Humedix's 'Liztuo' Sales Grow Fivefold, Offsetting Weak Fillers [Why Bio]
Predicted impact: Medium
Liztuo sales up fivefold offsetting weak fillers; meaningful for revenue mix.
Humedix휴메딕스
200670 · KOSDAQ · ₩200670 · 휴메딕스
₩22,700▼ ₩1,000 (4.22%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −55.92%
- Market cap
- ₩251B
- Enterprise value
- ₩142B
- P/E
- 5.5×
- P/B
- 0.8×
- Dividend yield
- 4.1%
- ROE
- 14.9%
- Net margin
- 25.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−56.9% from the high
₩21,050Today: ₩22,600 – ₩23,950₩52,700
Returns
- 1W−9.2%
- 1M−6.4%
- 3M−9.4%
- 6M−37.3%
- YTD−43.7%
- 1Y−53.9%
- Volume today
- 20,568
- 1.1× the 20-day average
- Traded today
- ₩475M
- Listed shares
- 11,045,930
- EPS (12 months)
- ₩4,156
- Earnings yield 18.3%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Strong growth in one product is partly offset by weaker fillers. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-7.9% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Humedix stock overview
Humedix (휴메딕스, KRX: 200670) is listed on KOSDAQ, in the Biotech & Pharma sector. Huons Co. Its shares closed at ₩22,700 on Oct 26, 2026, down 4.22% on the day, giving it a market value of ₩251B.
Key facts
- Market cap
- ₩251B
- Sector
- Biotech & Pharma
- Latest price change
- −4.22%
- As of
- Oct 26, 2026
- Main business
- Huons Co.
Quick answers about Humedix
- What does Humedix do?
- Huons Co. (Huminics) develops and supplies hyaluronic acid-based products for the global healthcare market, including dermal fillers, botulinum toxin (Lizetox), cosmetics, and knee osteoarthritis injections. It runs two business segments: an aesthetics segment selling fillers, toxins, dermo-cosmetics and medical devices, and a CMO segment manufacturing prescription injectables, osteoarthritis treatments, eye-care solutions and raw active ingredients such as hyaluronic acid, PDRN and heparin sodium.
- What is the market cap of Humedix?
- The market capitalisation of Humedix was ₩251B at the close on Oct 26, 2026.
- Who are the largest shareholders of Humedix?
- According to the latest official filings, the largest reported holders are Huons Global (37.52%, as of Apr 27, 2026); VIP Asset Management (4.51%, as of Feb 10, 2026); Yoon Yeon-sang (1.19%, as of Apr 27, 2026).
- When is the next earnings report from Humedix?
- Korean companies rarely announce results dates in advance. Based on when Humedix filed the same report in past years, its next 3q results is expected between Nov 10, 2026 and Nov 14, 2026.
- Does the National Pension Service own Humedix?
- Yes. The National Pension Service held 1.03% of Humedix shares as of Dec 31, 2025.
Company profile
Huons Co. (Huminics) develops and supplies hyaluronic acid-based products for the global healthcare market, including dermal fillers, botulinum toxin (Lizetox), cosmetics, and knee osteoarthritis injections. It runs two business segments: an aesthetics segment selling fillers, toxins, dermo-cosmetics and medical devices, and a CMO segment manufacturing prescription injectables, osteoarthritis treatments, eye-care solutions and raw active ingredients such as hyaluronic acid, PDRN and heparin sodium. The company sells across domestic and international markets.
Written by AI from the company's latest annual report.
- Korean name
- 휴메딕스
- Sector
- Biotech & Pharma
- CEO
- 강민종
- Founded
- Feb 2003
- Listed
- Dec 2014
- Listed shares
- 11,045,930
- Fiscal year ends
- Month 12
- Website
- www.humedix.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent news
Humedix extends distribution contract for filler 'Elavie' with China's Beijing Jingjing
Predicted impact: Low
China filler distribution extension already reported in the last 14 days; small.
Humedix Strengthens Push into China's Filler Market, Extends Local Distribution Contract
Predicted impact: Low
Distribution contract extension in China; no size disclosed and likely small versus revenue.
Recent filings
See all- Investor relations (IR) eventOct 21, 2026
- Share cancellation decisionSep 10, 2026
- Trust Contract Termination Result ReportSep 9, 2026
- Status Report on Acquisition Under Trust AgreementSep 9, 2026
- Investor relations (IR) eventAug 14, 2026
Titles in Korean until English translations are added.
Also known as: Humedix / 휴메딕스 / 200670 / KRX:200670
Source: KRX statistical information